Immunoassays are at the center of modern diagnostics. They detect the antibodies, hormones, proteins, and pathogens that drive decisions in oncology, cardiology, infectious disease, and neurology. Grand View Research values the global immunoassay market at about USD 28.1 billion in 2025. It expects USD 29.3 billion in 2026 and USD 40.3 billion by 2033, a CAGR of 4.6% from 2026 to 2033.
Below is where the market stands today, who is competing for share, and what is likely to shape the next few years.
Market Breakdown & Segmentation
The market is segmented by product, technology, application, specimen, end-use, and region. Here is the 2025 picture:
- Product: Reagents and kits lead with a 66.2% share. Software and services is the fastest-growing segment.
- Technology: Enzyme immunoassays (EIA) hold a 64.1% share. Rapid tests are expected to grow fastest.
- Application: Infectious disease leads with a 30.1% share and a projected 5.5% CAGR.
- Specimen: Blood leads with a 41.4% share. Urine is the fastest-growing specimen type.
- End-use: Hospitals lead with a 32.4% share. Clinical laboratories are poised for robust growth.
- Region: North America leads with a 47.3% share. Asia Pacific is the fastest-growing region.
Product. Reagents and kits dominate because every test run consumes them. Demand is steady across ELISA, chemiluminescence (CLIA), lateral flow, and rapid antigen formats. Software and services is smaller but growing fastest, as labs adopt automation, AI-enabled analytics, cloud data management, and outsourced testing support.
Technology. EIA's lead reflects its sensitivity, specificity, and compatibility with automated lab systems. Rapid tests are the challenger, helped by microfluidics, nanotechnology, and biosensor advances that make portable testing more accurate.
Application. Infectious disease testing leads, supported by persistent burdens such as tuberculosis (about 1.23 million deaths globally in 2024, per WHO). Oncology and autoimmune testing are also set to grow significantly as biomarker-driven care and companion diagnostics expand.
Specimen and end-use. Blood remains the workhorse sample type. Hospitals lead end-use because of their high testing volumes and investment in automated platforms. Urine-based testing is gaining ground in point-of-care and home settings because collection is non-invasive.
Region. North America's lead rests on advanced healthcare infrastructure, favorable reimbursement, and the presence of major manufacturers. Asia Pacific is expected to grow fastest as healthcare infrastructure improves, chronic disease burdens rise, and large patient populations gain access to diagnostics. China, Japan, and India are the key markets.
Major Competitors
The report profiles these major players:
- Abbott
- Siemens Healthineers
- Danaher Corporation (Beckman Coulter)
- bioMérieux
- QuidelOrtho (Quidel and Ortho Clinical Diagnostics)
- Sysmex Corporation
- Bio-Rad Laboratories
- F. Hoffmann-La Roche
- Becton, Dickinson and Company
- Thermo Fisher Scientific
Established players like Abbott compete on scale: automated high-throughput platforms, global distribution, deep R&D, and regulatory expertise. Their trade-offs are high compliance and manufacturing costs, long approval timelines, and platforms that can be hard to adopt in resource-limited settings.
Emerging players like QuidelOrtho focus on rapid, point-of-care, and cost-effective testing. They tend to move faster and adapt to regional needs, though they face smaller distribution networks and tighter resources for large-scale R&D.
Recent moves show where competition is heading:
- Roche completed its acquisition of LumiraDx's point-of-care technology in July 2024, broadening its decentralized testing platform.
- QuidelOrtho signed a supply agreement with Lifotronic in February 2026, adding analyzer platforms and more than 25 additional immunoassays.
- Fujirebio launched its Lumipulse G pTau 217 CSF assay in January 2026, and Roche received CE mark approval for its Elecsys pTau217 blood test in May 2026, both for Alzheimer's biomarker detection.
- Sysmex launched a research-use p-Tau217 assay kit in Europe in April 2026.
Neurodiagnostics, especially blood-based Alzheimer's testing, is becoming a visible battleground.
Want Deeper Insights? Download a Free Sample Report to see the report's structure, market data points, and forecasts.
Core Growth Drivers & Trends
Drivers
- The rise of chronic and infectious disease. According to WHO figures cited in the report, noncommunicable diseases cause roughly 74% of deaths worldwide. Cardiovascular disease, cancer, diabetes, and autoimmune disorders all require continuous diagnostic monitoring, which keeps immunoassay volumes high in hospitals and labs.
- Precision medicine. Immunoassays identify biomarkers that predict how patients will respond to specific therapies. Pharmaceutical companies are also building them into drug development pipelines, which supports demand for companion diagnostics.
- Automation. High-throughput analyzers improve lab efficiency, precision, and turnaround time, and they strengthen the case for centralized laboratory networks.
Trends
- Point-of-care expansion. Lateral flow, microfluidics, and digital immunoassays are moving testing into pharmacies, clinics, and homes. In August 2024, the U.S. FDA authorized the first over-the-counter home immunoassay for syphilis antibodies.
- Multiplexing and AI. Companies are pairing multiplex assays, CLIA, and AI-assisted interpretation to detect several biomarkers at once and improve specificity.
- Consolidation. Mergers, acquisitions, and supply agreements are increasing as companies build out point-of-care and immunochemistry portfolios.
- Regional localization. Partnerships, local manufacturing, and wider distribution networks are central to reaching emerging markets.
The main restraint
Cross-reactivity and false positives remain a challenge, particularly for rapid screening tests during overlapping respiratory outbreaks. Manufacturers are responding with multiplex platforms, CLIA, and AI-based interpretation to improve reliability.
The Bottom Line
The immunoassay market is growing at a steady 4.6% rather than a spectacular pace, but its foundations are strong: aging populations, rising chronic disease, personalized medicine, and a shift toward faster, more decentralized testing. Companies that combine automation, strong biomarker menus, and point-of-care reach will be best placed to capture growth, especially in Asia Pacific.
Customize This Report to add regions, segments, or data points that match your strategy. Grand View Research offers 20% free customization.
